bicuculline has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Covolan, L; de Castro, AC; de Oliveira, JA; de Souza, AS; Del Bel, EA; Mograbi, KM; Sales, PJ | 1 |
| Bargas, J; Carrillo-Reid, L; Drucker-Colin, R; Fiordelisio, T; Galarraga, E; López-Huerta, VG; Tapia, D | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Volta, M | 1 |
| Matsumura, M | 1 |
| Aziz, TZ; Giladi, N; Nandi, D; Stein, JF; Winter, J | 1 |
| Aziz, TZ; Jenkinson, N; Nandi, D; Stein, JF | 1 |
| Marti, M; Morari, M; Trapella, C; Viaro, R | 1 |
1 review(s) available for bicuculline and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Experimental parkinsonism in primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Apomorphine; Basal Ganglia; Bicuculline; Cerebral Cortex; Disease Models, Animal; Dopamine; Dopamine Agonists; Electrocoagulation; GABA Antagonists; Globus Pallidus; Humans; Models, Neurological; MPTP Poisoning; Muscle Rigidity; Neurotoxins; Parkinsonian Disorders; Primates; Substance-Related Disorders; Substantia Nigra; Tegmentum Mesencephali; Thalamus | 2001 |
1 trial(s) available for bicuculline and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Laboratory and clinical investigations of the region of the rostral brainstem in motor control.
Topics: Animals; Antiparkinson Agents; Bicuculline; Deep Brain Stimulation; Dose-Response Relationship, Radiation; Female; GABA Antagonists; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Retrospective Studies | 2006 |
5 other study(ies) available for bicuculline and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Effects of GABAa receptor antagonists on motor behavior in pharmacological Parkinson's disease model in mice.
Topics: Animals; Behavior, Animal; Bicuculline; Disease Models, Animal; Flumazenil; GABA-A Receptor Antagonists; Gait; Mice; Motor Activity; Parkinsonian Disorders | 2017 |
The balance of striatal feedback transmission is disrupted in a model of parkinsonism.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Adrenergic Agents; Anesthetics, Local; Animals; Animals, Newborn; Bicuculline; Biophysics; Calcium; Disease Models, Animal; Electric Stimulation; Excitatory Amino Acid Antagonists; Feedback, Physiological; GABA Antagonists; gamma-Aminobutyric Acid; Green Fluorescent Proteins; In Vitro Techniques; Lidocaine; Lysine; Male; Mice; Mice, Transgenic; Monte Carlo Method; Neostriatum; Neural Inhibition; Neural Pathways; Neurons; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Pyridazines; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission; Time Factors; Valine | 2013 |
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Bicuculline; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hindlimb Suspension; Male; Microdialysis; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thiophenes; Time Factors | 2008 |
Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bicuculline; Cholinergic Fibers; Female; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Levodopa; Macaca mulatta; Male; Motor Activity; Neural Inhibition; Neural Pathways; Parkinsonian Disorders; Pons; Receptors, GABA-A; Recovery of Function; Tegmentum Mesencephali; Treatment Outcome | 2002 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus | 2007 |